Phosphodiesterase-3 inhibitor

This page covers all Phosphodiesterase-3 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PDE-3 (phosphodiesterase-3), PDE-3 (Phosphodiesterase-3), cGMP-inhibited 3',5'-cyclic phosphodiesterase A.

Targets

PDE-3 (phosphodiesterase-3) · PDE-3 (Phosphodiesterase-3) · cGMP-inhibited 3',5'-cyclic phosphodiesterase A · Phosphodiesterase 3 · Phosphodiesterase 3 (PDE3)

Marketed (7)

• Pletaal SR capsule · Korea Otsuka Pharmaceutical Co., Ltd. · Cardiovascular
  Cilostazol inhibits phosphodiesterase-3 (PDE-3) to increase cAMP levels, promoting vasodilation and inhibiting platelet aggregation.
• Cilostazol Tablets · Gyeongsang National University Hospital · Cardiovascular
  Cilostazol inhibits phosphodiesterase-3 (PDE-3) to increase cAMP levels, promoting vasodilation and inhibiting platelet aggregation.
• Ohtuvayre · Verona Pharma · Respiratory
  Ohtuvayre works by blocking an enzyme called phosphodiesterase 3, which helps to increase the levels of a molecule called cyclic AMP in the lungs.
• Pletal · Otsuka · Metabolic
• Cilostazol group · Otsuka Beijing Research Institute · Cardiovascular
  Cilostazol inhibits phosphodiesterase-3 (PDE-3) to increase cAMP levels, promoting vasodilation and inhibiting platelet aggregation.
• Primacor · Sanofi · Cardiovascular
• Primacor · Sanofi

Phase 3 pipeline (2)

• intravenous milrinone · Konkuk University Medical Center · Cardiovascular
  Milrinone is a phosphodiesterase 3 inhibitor that increases cardiac contractility and vasodilation.
• Anagrelide retard · AOP Orphan Pharmaceuticals AG · Hematology/Oncology
  Anagrelide is a phosphodiesterase 3 inhibitor that reduces platelet production by inhibiting megakaryocyte maturation and proliferation.

Patent intelligence

• phosphodiesterase 3 inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates